NASDAQ:MGX Metagenomi Q3 2026 Earnings Date & Estimates $0.86 -0.06 (-6.12%) Closing price 04:00 PM EasternExtended Trading$0.86 +0.00 (+0.44%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Metagenomi is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. The conference call is scheduled for 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Metagenomi in Q3 2026Metagenomi is expected to post earnings of -$0.6395 per share on revenue of $2.58 million. In the same quarter a year earlier Metagenomi reported -$0.55 per share on revenue of $8.66 million. Metagenomi last reported on August 10, 2026, posting -$0.73 per share and missing the -$0.5531 consensus estimate. Metagenomi has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.6395Expected Revenue$2.58 millionPrior-Year EPS-$0.55Prior-Year Revenue$8.66 millionExpected Revenue Growth-70.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.73 (Missed by -$0.1769)Last Quarter Revenue($0.26) millionEPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Metagenomi Q3 2026 Earnings FAQ When does Metagenomi report Q3 2026 earnings? Metagenomi (NASDAQ:MGX) is estimated to report Q3 2026 earnings on Tuesday, November 10, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Metagenomi's Q3 2026 earnings call? Metagenomi's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Metagenomi? Analysts expect Metagenomi to post earnings of -$0.6395 per share for Q3 2026. How much revenue is Metagenomi expected to report? The consensus revenue estimate for Metagenomi is $2.58 million for Q3 2026. Metagenomi Earnings HeadlinesMetagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare ConferenceOctober 13 at 8:00 AM | globenewswire.comMetagenomi (NASDAQ:MGX) Stock Price Down 7.7% - What's Next?October 3, 2026 | americanbankingnews.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Metagenomi updates hemophilia A gene editing programSeptember 22, 2026 | tipranks.comMetagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare ConferenceSeptember 1, 2026 | globenewswire.comMetagenomi Therapeutics Inc MGXAugust 25, 2026 | morningstar.comMSee More Metagenomi Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Metagenomi? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Metagenomi and other key companies, straight to your email. Email Address About MetagenomiMetagenomi (NASDAQ:MGX) is a biotechnology company focused on developing genetic medicines using gene-editing technologies. The company applies metagenomics, the study of genetic material recovered directly from environmental samples, to identify naturally occurring CRISPR and other genome-editing systems that may offer advantages over established tools. Metagenomi is developing a pipeline of investigational therapies designed to address genetic diseases through in vivo and ex vivo gene editing. Its research activities include discovering and engineering novel editing systems, delivery methods and therapeutic approaches for potential use in human medicine. The company’s programs remain in development, and it does not have commercially marketed products. Founded in 2018, Metagenomi is headquartered in Emeryville, California, and has pursued collaborations with pharmaceutical and biotechnology companies to advance its gene-editing platform. Brian C. Thomas, a co-founder of the company, serves as chief executive officer. Metagenomi began trading on the Nasdaq under the symbol MGX following its initial public offering in 2024.View Metagenomi ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
